Symbols / TGTX Stock $37.95 -0.94% TG Therapeutics, Inc.
TGTX (Stock) Chart
About
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Stock Fundamentals
Scroll to Statements| Market Cap | 6.06B | Enterprise Value | 5.77B | Income | 447.18M | Sales | 616.29M | Book/sh | 4.52 | Cash/sh | 0.96 |
| Dividend Yield | — | Payout | 0.00% | Employees | 399 | IPO | — | P/E | 13.70 | Forward P/E | 15.97 |
| PEG | 1.61 | P/S | 9.83 | P/B | 8.39 | P/C | — | EV/EBITDA | 46.76 | EV/Sales | 9.36 |
| Quick Ratio | 2.91 | Current Ratio | 4.10 | Debt/Eq | 39.26 | LT Debt/Eq | — | EPS (ttm) | 2.77 | EPS next Y | 2.38 |
| EPS Growth | -6.10% | Revenue Growth | 78.00% | Earnings | 2026-05-04 | ROA | 9.39% | ROE | 102.75% | ROIC | — |
| Gross Margin | 83.66% | Oper. Margin | 26.22% | Profit Margin | 72.56% | Shs Outstand | 159.69M | Shs Float | 140.95M | Short Float | 23.66% |
| Short Ratio | 13.58 | Short Interest | — | 52W High | 46.48 | 52W Low | 25.28 | Beta | 1.75 | Avg Volume | 1.86M |
| Volume | 462.95K | Target Price | $44.57 | Recom | Buy | Prev Close | $38.31 | Price | $37.95 | Change | -0.94% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | main | JP Morgan | Overweight → Overweight | $46 |
| 2026-01-15 | main | Goldman Sachs | Neutral → Neutral | $39 |
| 2025-11-03 | main | JP Morgan | Overweight → Overweight | $49 |
| 2025-09-17 | main | B. Riley Securities | Buy → Buy | $55 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $55 |
| 2025-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $55 |
| 2024-11-25 | main | JP Morgan | Overweight → Overweight | $43 |
| 2024-11-05 | main | HC Wainwright & Co. | Buy → Buy | $55 |
| 2024-11-05 | main | Goldman Sachs | Neutral → Neutral | $22 |
| 2024-10-29 | init | TD Cowen | — → Buy | $50 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-08-07 | main | B. Riley Securities | Buy → Buy | $34 |
| 2024-08-07 | main | Goldman Sachs | Neutral → Neutral | $20 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-05-02 | main | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-05-02 | main | Ladenburg Thalmann | Buy → Buy | $40 |
| 2024-04-18 | reit | HC Wainwright & Co. | Buy → Buy | $45 |
| 2024-04-18 | reit | JP Morgan | Overweight → Overweight | $25 |
| 2024-04-18 | reit | Ladenburg Thalmann | Buy → Buy | $39 |
| 2024-03-01 | reit | HC Wainwright & Co. | Buy → Buy | $45 |
- New BRIUMVI studies in relapsing MS to be shown at AAN 2026 - Stock Titan Wed, 22 Apr 2026 11
- TG Therapeutics Stock: Flawless Execution $500M Non-Dilutive Boost Outlook (NASDAQ:TGTX) - Seeking Alpha Sun, 19 Apr 2026 02
- TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside - ChartMill Mon, 20 Apr 2026 12
- TG Therapeutics Inc. (TGTX) posts 87.3 percent year over year revenue growth despite large Q4 2025 earnings miss. - Xã Thanh Hà hu, 23 Apr 2026 09
- TG Therapeutics Inc. (TGTX) posts 87.3 percent year over year revenue growth despite large Q4 2025 earnings miss. - Social Momentum Signals - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 00
- Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI Phase 3 Subcutaneous Trial Milestone - simplywall.st Mon, 20 Apr 2026 04
- TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance Fri, 31 Oct 2025 07
- TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN Mon, 20 Apr 2026 19
- TG Therapeutics, Inc. (TGTX) Stock Analysis: A 55.89% Potential Upside in the Biotech Space - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - ChartMill Wed, 22 Apr 2026 11
- Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Weakness And BRIUMVI Growth Assumptions - Yahoo Finance ue, 27 Jan 2026 08
- Has The Market Mispriced TG Therapeutics (TGTX) After Recent Biotech Sector Coverage Swings? - simplywall.st Fri, 17 Apr 2026 20
- MS trial completion moves TG closer to at-home BRIUMVI option - Stock Titan Wed, 15 Apr 2026 11
- TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum - ChartMill Sat, 04 Apr 2026 07
- BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance ue, 10 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
616.29
+87.32%
|
329.00
+40.80%
|
233.66
+8290.02%
|
2.79
|
| Operating Revenue |
|
616.29
+87.32%
|
329.00
+40.80%
|
233.66
+8290.02%
|
2.79
|
| Cost Of Revenue |
|
100.71
+161.69%
|
38.49
+172.35%
|
14.13
+5232.45%
|
0.27
|
| Reconciled Cost Of Revenue |
|
100.71
+161.69%
|
38.49
+172.35%
|
14.13
+5232.45%
|
0.27
|
| Gross Profit |
|
515.57
+77.47%
|
290.52
+32.34%
|
219.53
+8611.55%
|
2.52
|
| Operating Expense |
|
392.25
+57.79%
|
248.59
+24.98%
|
198.90
-9.93%
|
220.84
|
| Research And Development |
|
160.22
+69.92%
|
94.29
+23.75%
|
76.19
-39.22%
|
125.35
|
| Selling General And Administration |
|
232.03
+50.38%
|
154.30
+25.75%
|
122.71
+28.51%
|
95.48
|
| Selling And Marketing Expense |
|
—
|
—
|
—
|
64.05
|
| General And Administrative Expense |
|
232.03
+50.38%
|
154.30
+25.75%
|
122.71
+28.51%
|
95.48
|
| Salaries And Wages |
|
48.05
+53.13%
|
31.38
+25.91%
|
24.92
-20.72%
|
31.44
|
| Other Gand A |
|
183.98
+49.68%
|
122.92
+25.70%
|
97.78
+52.68%
|
64.05
|
| Total Expenses |
|
492.96
+71.72%
|
287.07
+34.76%
|
213.03
-3.65%
|
221.10
|
| Operating Income |
|
123.32
+194.13%
|
41.93
+103.21%
|
20.63
+109.45%
|
-218.32
|
| Total Operating Income As Reported |
|
123.32
+194.13%
|
41.93
+103.21%
|
20.63
+109.45%
|
-218.32
|
| EBITDA |
|
134.36
+169.25%
|
49.90
+91.20%
|
26.10
+112.25%
|
-213.11
|
| Normalized EBITDA |
|
134.36
+169.25%
|
49.90
+91.20%
|
26.10
+112.25%
|
-213.11
|
| Reconciled Depreciation |
|
0.24
-12.86%
|
0.28
-33.81%
|
0.42
-17.86%
|
0.52
|
| EBIT |
|
134.12
+170.28%
|
49.62
+93.25%
|
25.68
+112.02%
|
-213.62
|
| Net Income |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Pretax Income |
|
107.39
+319.59%
|
25.59
+95.94%
|
13.06
+105.84%
|
-223.81
|
| Net Non Operating Interest Income Expense |
|
-26.73
-11.23%
|
-24.03
-90.47%
|
-12.62
-23.79%
|
-10.19
|
| Interest Expense Non Operating |
|
26.73
+11.23%
|
24.03
+90.47%
|
12.62
+23.79%
|
10.19
|
| Net Interest Income |
|
-26.73
-11.23%
|
-24.03
-90.47%
|
-12.62
-23.79%
|
-10.19
|
| Interest Expense |
|
26.73
+11.23%
|
24.03
+90.47%
|
12.62
+23.79%
|
10.19
|
| Other Income Expense |
|
10.79
+40.30%
|
7.69
+52.52%
|
5.04
+7.43%
|
4.70
|
| Other Non Operating Income Expenses |
|
10.79
+40.30%
|
7.69
+52.52%
|
5.04
+7.43%
|
4.70
|
| Tax Provision |
|
-339.79
-15468.11%
|
2.21
+466.92%
|
0.39
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+143.09%
|
0.00
+189.33%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Net Income From Continuing And Discontinued Operation |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Net Income Continuous Operations |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Normalized Income |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Net Income Common Stockholders |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Diluted EPS |
|
2.77
+1746.67%
|
0.15
+66.67%
|
0.09
+106.16%
|
-1.46
|
| Basic EPS |
|
3.10
+1837.50%
|
0.16
+77.78%
|
0.09
+106.16%
|
-1.46
|
| Basic Average Shares |
|
144.32
-0.69%
|
145.32
+2.37%
|
141.96
+4.83%
|
135.41
|
| Diluted Average Shares |
|
161.41
+0.67%
|
160.34
+7.96%
|
148.51
+9.67%
|
135.41
|
| Diluted NI Availto Com Stockholders |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,063.25
+84.05%
|
577.69
+75.28%
|
329.59
+70.27%
|
193.57
|
| Current Assets |
|
630.76
+11.37%
|
566.36
+78.13%
|
317.94
+88.94%
|
168.27
|
| Cash Cash Equivalents And Short Term Investments |
|
141.97
-54.35%
|
311.00
+42.98%
|
217.51
+34.53%
|
161.68
|
| Cash And Cash Equivalents |
|
79.15
-56.00%
|
179.89
+93.57%
|
92.93
-9.16%
|
102.30
|
| Other Short Term Investments |
|
62.82
-52.08%
|
131.11
+5.24%
|
124.58
+109.81%
|
59.37
|
| Receivables |
|
305.63
+136.58%
|
129.19
+152.84%
|
51.09
|
0.00
|
| Accounts Receivable |
|
305.63
+136.58%
|
129.19
+152.84%
|
51.09
|
0.00
|
| Inventory |
|
125.59
+13.70%
|
110.46
+177.37%
|
39.82
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
4.18
-1.27%
|
4.24
|
| Other Current Assets |
|
57.58
+266.38%
|
15.72
+65.10%
|
9.52
+303.52%
|
2.36
|
| Total Non Current Assets |
|
432.49
+3716.87%
|
11.33
-2.69%
|
11.64
-53.97%
|
25.30
|
| Net PPE |
|
6.28
-12.21%
|
7.15
-11.17%
|
8.05
-25.61%
|
10.82
|
| Gross PPE |
|
6.28
-12.21%
|
7.15
-11.17%
|
8.05
-25.61%
|
10.82
|
| Properties |
|
—
|
—
|
0.00
|
0.00
|
| Other Properties |
|
6.28
-12.21%
|
7.15
-11.17%
|
8.05
-12.45%
|
9.20
|
| Leases |
|
—
|
—
|
1.42
-13.03%
|
1.63
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
0.80
+0.00%
|
0.80
|
| Goodwill |
|
—
|
—
|
0.80
+0.00%
|
0.80
|
| Investments And Advances |
|
74.83
+9160.52%
|
0.81
|
0.00
-100.00%
|
12.40
|
| Long Term Equity Investment |
|
15.69
|
0.00
|
—
|
—
|
| Non Current Deferred Assets |
|
348.00
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Assets |
|
348.00
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
3.39
+0.42%
|
3.37
-6.18%
|
3.59
+182.33%
|
1.27
|
| Total Liabilities Net Minority Interest |
|
415.23
+16.86%
|
355.33
+110.15%
|
169.09
+25.26%
|
134.99
|
| Current Liabilities |
|
153.76
+69.57%
|
90.68
+68.80%
|
53.72
+0.98%
|
53.20
|
| Payables And Accrued Expenses |
|
107.51
+84.42%
|
58.30
+51.53%
|
38.47
-8.44%
|
42.02
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
21.85
+43.89%
|
15.19
+24.75%
|
12.17
+44.35%
|
8.43
|
| Current Debt And Capital Lease Obligation |
|
1.04
-9.77%
|
1.16
-19.99%
|
1.45
-8.54%
|
1.58
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
1.04
-9.77%
|
1.16
-19.99%
|
1.45
-8.54%
|
1.58
|
| Current Deferred Liabilities |
|
21.23
+86.03%
|
11.41
+7409.21%
|
0.15
|
—
|
| Current Deferred Revenue |
|
21.23
+86.03%
|
11.41
+7409.21%
|
0.15
|
—
|
| Other Current Liabilities |
|
2.12
-54.10%
|
4.63
+212.85%
|
1.48
+26.52%
|
1.17
|
| Total Non Current Liabilities Net Minority Interest |
|
261.47
-1.20%
|
264.65
+129.40%
|
115.36
+41.06%
|
81.78
|
| Long Term Debt And Capital Lease Obligation |
|
252.67
+0.04%
|
252.56
+130.97%
|
109.35
+34.21%
|
81.48
|
| Long Term Debt |
|
245.65
+0.50%
|
244.43
+144.14%
|
100.12
+40.74%
|
71.14
|
| Long Term Capital Lease Obligation |
|
7.02
-13.67%
|
8.13
-11.89%
|
9.23
-10.76%
|
10.34
|
| Non Current Deferred Liabilities |
|
8.81
-27.12%
|
12.09
+100.88%
|
6.02
+1872.46%
|
0.30
|
| Non Current Deferred Revenue |
|
8.81
-27.12%
|
12.09
+100.88%
|
6.02
+1872.46%
|
0.30
|
| Stockholders Equity |
|
648.02
+191.42%
|
222.36
+38.54%
|
160.50
+173.95%
|
58.59
|
| Common Stock Equity |
|
648.02
+191.42%
|
222.36
+38.54%
|
160.50
+173.95%
|
58.59
|
| Capital Stock |
|
0.16
+1.92%
|
0.16
+3.31%
|
0.15
+3.42%
|
0.15
|
| Common Stock |
|
0.16
+1.92%
|
0.16
+3.31%
|
0.15
+3.42%
|
0.15
|
| Share Issued |
|
158.85
+1.69%
|
156.20
+3.13%
|
151.47
+3.44%
|
146.43
|
| Ordinary Shares Number |
|
155.31
-0.34%
|
155.84
+2.91%
|
151.42
+3.44%
|
146.39
|
| Treasury Shares Number |
|
3.54
+863.20%
|
0.37
+790.61%
|
0.04
+0.00%
|
0.04
|
| Additional Paid In Capital |
|
1,830.11
+3.96%
|
1,760.40
+2.76%
|
1,713.16
+8.04%
|
1,585.71
|
| Retained Earnings |
|
-1,082.02
+29.24%
|
-1,529.19
+1.51%
|
-1,552.58
-1.67%
|
-1,527.03
|
| Treasury Stock |
|
100.23
+1014.45%
|
8.99
+3743.59%
|
0.23
+0.00%
|
0.23
|
| Total Equity Gross Minority Interest |
|
648.02
+191.42%
|
222.36
+38.54%
|
160.50
+173.95%
|
58.59
|
| Total Capitalization |
|
893.66
+91.45%
|
466.79
+79.11%
|
260.62
+100.91%
|
129.72
|
| Working Capital |
|
477.00
+0.28%
|
475.68
+80.03%
|
264.22
+129.61%
|
115.07
|
| Invested Capital |
|
893.66
+91.45%
|
466.79
+79.11%
|
260.62
+100.91%
|
129.72
|
| Total Debt |
|
253.71
0.00%
|
253.72
+129.00%
|
110.80
+33.39%
|
83.06
|
| Net Debt |
|
166.50
+157.99%
|
64.53
+798.19%
|
7.18
|
—
|
| Capital Lease Obligations |
|
8.06
-13.19%
|
9.29
-12.99%
|
10.68
-10.47%
|
11.93
|
| Net Tangible Assets |
|
648.02
+191.42%
|
222.36
+38.54%
|
160.50
+177.74%
|
57.79
|
| Tangible Book Value |
|
648.02
+191.42%
|
222.36
+38.54%
|
160.50
+177.74%
|
57.79
|
| Held To Maturity Securities |
|
59.14
+7218.81%
|
0.81
|
0.00
-100.00%
|
12.40
|
| Investmentin Financial Assets |
|
59.14
+7218.81%
|
0.81
|
0.00
-100.00%
|
12.40
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.77
+38.86%
|
-40.52
-28.98%
|
-31.41
+82.17%
|
-176.17
|
| Cash Flow From Continuing Operating Activities |
|
-24.77
+38.86%
|
-40.52
-28.98%
|
-31.41
+82.17%
|
-176.17
|
| Net Income From Continuing Operations |
|
447.18
+1812.41%
|
23.38
+84.52%
|
12.67
+105.66%
|
-223.81
|
| Depreciation Amortization Depletion |
|
0.24
-12.86%
|
0.28
-33.81%
|
0.42
-17.86%
|
0.52
|
| Depreciation |
|
0.24
-12.86%
|
0.28
-33.81%
|
0.42
-17.86%
|
0.52
|
| Depreciation And Amortization |
|
0.24
-12.86%
|
0.28
-33.81%
|
0.42
-17.86%
|
0.52
|
| Other Non Cash Items |
|
2.99
-28.77%
|
4.20
-5.73%
|
4.45
+0.25%
|
4.44
|
| Stock Based Compensation |
|
64.67
+52.02%
|
42.54
+12.15%
|
37.93
-15.07%
|
44.66
|
| Provisionand Write Offof Assets |
|
6.17
|
0.00
|
0.00
|
—
|
| Deferred Tax |
|
-348.00
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
-348.00
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
—
|
4.61
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.30
-60.48%
|
0.75
|
0.00
|
0.00
|
| Change In Working Capital |
|
-194.54
-77.99%
|
-109.30
-29.10%
|
-84.66
-5040.19%
|
-1.65
|
| Change In Receivables |
|
-176.44
-125.94%
|
-78.09
-52.84%
|
-51.09
-3778.40%
|
1.39
|
| Changes In Account Receivables |
|
-176.44
-125.94%
|
-78.09
-52.84%
|
-51.09
-3778.40%
|
1.39
|
| Change In Inventory |
|
-33.45
+49.96%
|
-66.85
-80.98%
|
-36.94
|
0.00
|
| Change In Payables And Accrued Expense |
|
55.88
+144.67%
|
22.84
+11794.79%
|
0.19
+101.74%
|
-11.01
|
| Change In Other Working Capital |
|
6.39
-63.45%
|
17.48
+206.13%
|
5.71
+3857.24%
|
-0.15
|
| Change In Other Current Assets |
|
-42.43
-571.79%
|
-6.32
-123.10%
|
-2.83
-134.60%
|
8.18
|
| Change In Other Current Liabilities |
|
-4.48
-373.00%
|
1.64
+447.00%
|
0.30
+645.45%
|
-0.06
|
| Investing Cash Flow |
|
13.80
+1431.95%
|
-1.04
+97.95%
|
-50.65
-153.09%
|
-20.01
|
| Cash Flow From Continuing Investing Activities |
|
13.80
+1431.95%
|
-1.04
+97.95%
|
-50.65
-153.09%
|
-20.01
|
| Net PPE Purchase And Sale |
|
-0.21
-375.56%
|
-0.04
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
-0.21
-375.56%
|
-0.04
|
0.00
+100.00%
|
-0.01
|
| Capital Expenditure |
|
-0.21
-375.56%
|
-0.04
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
14.01
+1514.03%
|
-0.99
+98.04%
|
-50.65
-153.27%
|
-20.00
|
| Purchase Of Investment |
|
-223.49
+28.34%
|
-311.89
-112.34%
|
-146.88
-36.92%
|
-107.27
|
| Sale Of Investment |
|
237.50
-23.61%
|
310.90
+223.08%
|
96.23
+10.26%
|
87.28
|
| Financing Cash Flow |
|
-89.73
-169.81%
|
128.53
+76.78%
|
72.70
+18694.63%
|
-0.39
|
| Cash Flow From Continuing Financing Activities |
|
-89.73
-169.81%
|
128.53
+76.78%
|
72.70
+18694.63%
|
-0.39
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
137.26
+449.05%
|
25.00
+2664.10%
|
-0.97
|
| Issuance Of Debt |
|
0.00
-100.00%
|
244.81
+879.26%
|
25.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-107.55
|
0.00
+100.00%
|
-0.97
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
244.81
+879.26%
|
25.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-107.55
|
0.00
+100.00%
|
-0.97
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
137.26
+449.05%
|
25.00
+2664.10%
|
-0.97
|
| Net Common Stock Issuance |
|
-91.24
-941.55%
|
-8.76
-118.92%
|
46.30
|
0.00
|
| Common Stock Payments |
|
-91.24
-941.55%
|
-8.76
|
0.00
|
0.00
|
| Cash Dividends Paid |
|
—
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-91.24
-941.55%
|
-8.76
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.51
+65.32%
|
0.91
-40.42%
|
1.53
+162.67%
|
0.58
|
| Net Other Financing Charges |
|
—
|
-0.89
-611.20%
|
-0.12
|
—
|
| Changes In Cash |
|
-100.70
-215.78%
|
86.97
+1029.31%
|
-9.36
+95.24%
|
-196.57
|
| Beginning Cash Position |
|
181.19
+92.31%
|
94.22
-9.04%
|
103.58
-65.49%
|
300.15
|
| End Cash Position |
|
80.49
-55.58%
|
181.19
+92.31%
|
94.22
-9.04%
|
103.58
|
| Free Cash Flow |
|
-24.99
+38.40%
|
-40.56
-29.12%
|
-31.41
+82.17%
|
-176.18
|
| Interest Paid Supplemental Data |
|
24.25
+31.29%
|
18.47
+110.58%
|
8.77
+61.08%
|
5.45
|
| Income Tax Paid Supplemental Data |
|
7.88
+1475.80%
|
0.50
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-3.79
+45.76%
|
-6.98
-212.34%
|
-2.24
-575.53%
|
-0.33
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
46.30
|
0.00
|
| Interest Paid CFF |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
46.30
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-20 View
- 10-K2026-02-27 View
- 8-K2026-02-26 View
- 42026-01-29 View
- 8-K2026-01-13 View
- 42026-01-09 View
- 42026-01-09 View
- 42025-11-25 View
- 42025-11-07 View
- 10-Q2025-11-05 View
- 8-K2025-11-03 View
- 42025-09-12 View
- 10-Q2025-08-08 View
- 8-K2025-08-04 View
- 42025-06-16 View
- 42025-06-16 View
- 42025-06-16 View
- 42025-06-16 View
- 42025-06-16 View
- 8-K2025-06-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|